EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Targeting metabolic reprogramming in glioblastoma as a new strategy to overcome therapy resistance

Simona D'Aprile, Simona Denaro, Anna Gervasi, Nunzio Vicario, Rosalba Parenti

Frontiers in Cell and Developmental Biology · 26.02.2025 · 13

DOI: 10.3389/fcell.2025.1535073 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Cell and Developmental Biology, online erschienen am 26.02.2025. Verfasst von Simona D'Aprile und 4 weiteren Autor:innen. Beteiligte Einrichtung: Section of Physiology, Department of Biomedical and Biotechnological Sciences, University of Catania, Catania, Italy. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 122 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glioblastoma (GBM) is one of the deadliest tumors due to its high aggressiveness and resistance to standard therapies, resulting in a dismal prognosis. This lethal tumor carries out metabolic reprogramming in order to modulate specific pathways, providing metabolites that promote GBM cells proliferation and limit the efficacy of standard treatments. Indeed, GBM remodels glucose metabolism and undergoes Warburg effect, fuelling glycolysis even when oxygen is available. Moreover, recent evidence revealed a rewiring in nucleotide, lipid and iron metabolism, resulting not only in an increased tumor growth, but also in radio- and chemo-resistance. Thus, while on the one hand metabolic reprogramming is an advantage for GBM, on the other hand it may represent an exploitable target to hamper GBM progression. Lately, a number of studies focused on drugs targeting metabolism to uncover their effects on tumor proliferation and therapy resistance, demonstrating that some of these are effective, in combination with conventional treatments, sensitizing GBM to radiotherapy and chemotherapy. However, GBM heterogeneity could lead to a plethora of metabolic alterations among subtypes, hence a metabolic treatment might be effective for proneural tumors but not for mesenchymal ones, which are more aggressive and resistant to conventional approaches. This review explores key mechanisms of GBM metabolic reprogramming and their involvement in therapy resistance, highlighting how metabolism acts as a double-edged sword for GBM, taking into account metabolic pathways that seem to offer promising treatment options for GBM.

Schlagwörter

Stichwörter der Autor:innen

Warburg effectchemotherapyironlipidsmetabolismnucleotidesradiotherapytumor microenvironment

Autor:innen und Institutionen

  • Section of Physiology, Department of Biomedical and Biotechnological Sciences, University of Catania, Catania, Italy.

Zitieren

APA

D'Aprile, S., Denaro, S., Gervasi, A., Vicario, N., & Parenti, R. (2025). Targeting metabolic reprogramming in glioblastoma as a new strategy to overcome therapy resistance. Frontiers in Cell and Developmental Biology, 13. https://doi.org/10.3389/fcell.2025.1535073

Vancouver

D'Aprile S, Denaro S, Gervasi A, Vicario N, Parenti R. Targeting metabolic reprogramming in glioblastoma as a new strategy to overcome therapy resistance. Frontiers in Cell and Developmental Biology. 2025;13. doi:10.3389/fcell.2025.1535073

BibTeX
@article{DAprile2025,
  author = {D'Aprile, Simona and Denaro, Simona and Gervasi, Anna and Vicario, Nunzio and Parenti, Rosalba},
  title = {Targeting metabolic reprogramming in glioblastoma as a new strategy to overcome therapy resistance},
  journal = {Frontiers in Cell and Developmental Biology},
  year = {2025},
  volume = {13},
  doi = {10.3389/fcell.2025.1535073}
}
Kostenlos starten →